Rising Prevalence of Respiratory Disorders to Propel the Demand for Smart Inhalers
The increasing prevalence of respiratory disorders like asthma and COPD majorly contributes to driving the growth of the global smart inhalers market. Increasing prevalence has led to a surge in the demand for efficient respiratory care, in recent years. Moreover, it is also observed that the healthcare professionals, especially in developed regions are getting inclined towards the adoption of smart inhalers for the delivery of drugs directly to the respiratory tract of patients so as to increase the efficacy of drug delivery and maintain track record.
Get Sample Copy Of This @ https://www.persistencemarketresearch.com/samples/26881
Technological Advancements Favor the Development of Smart Inhalers
Nowadays, connected devices for asthma and COPD, especially smart inhalers, which accurately monitor, track, and prompt medication use are extensively available. Smart inhalers are robust, accurate, and collect clinical data. The respiratory inhalers available at present are insufficient for the adequate treatment of asthma and COPD. Physicians often lack the tools and information to understand the patient's state of health. This scenario suggests that rather than simply offering incrementally better medicines, smart inhalers provide new ways of delivering and activating patient self-management. Connected inhalers benefit from the miniaturization of flow sensors to evaluate the volume of medication inhaled. For instance, Sensirion, a Switzerland-based company, has developed SDP3x (a differential pressure sensor), which can be integrated into smart inhalers. Miniaturization also enables the development of systems, making them furthermore user-friendly.
Smart Inhalers Increase Medical Adherence, Improve Outcomes, and Reduce Treatment Costs
The treatment cost associated with respiratory disorders is generally considered as a major issue for payers, patients, and prescribers. Presently, in order to reduce the burden, prominent respiratory pharmaceutical and digital health companies are forming strategic partnerships in order to develop new technologies and pave way for innovation in digital healthcare. Smart inhalers are introduced as a novel approach to promote adherence by monitoring medication use on the basis of respiratory disorders. It is also observed that there is a significant opportunity for smart inhalers to improve outcomes and reduce treatment costs. In clinical studies, 80% adherence to preventative medication has been observed among asthma patients using smart inhalers, with a 61% reduction in oral steroid use. This could significantly reduce the overall costs associated with the treatment of respiratory disorders and increase the adoption of smart inhalers.
Digital Health Partnerships Between Smart Inhaler Manufacturers and Software Companies
Leading manufacturers of smart inhalers are focusing on collaborating with digital and software companies in order to serve the targeted population. Moreover, such collaborations also help manufacturers launch their products more conveniently as well as enhance their distribution channels. Propeller Health, a leading digital health solution provider for respiratory medicine, collaborated with Novartis AG to develop a custom add-on sensor for the Breezhaler inhaler, a smart inhaler used for COPD treatment. AstraZeneca plc formed a digital health partnership with the digital health company Adherium to manufacture smart inhalers.
Lack of Awareness Regarding Symptoms of Asthma and COPD Expected to Hamper Growth of the Smart Inhalers Market
The lack of awareness regarding the symptoms of asthma and COPD has resulted in a vast majority of people suffering from respiratory illnesses remaining undiagnosed and, therefore, untreated. This is a major factor hampering the growth of the global smart inhalers market. A majority of people with COPD symptoms are unaware about the disease and low-economy countries account for 90% of the deaths related to COPD. The use of smart inhalers is not yet widely supported within the public health system. This can be attributed to the limited reimbursement scenario and low awareness among patients regarding the technology. Moreover, the limited availability of the device creates an obstacle, which would directly affect the overall growth of the smart inhalers market as per the current scenario.
The competition section of the report features profiles of key players operating in the smart inhalers market based on their market share, product offerings, and differential product marketing strategies. Few key players featured in the smart inhalers market report include GlaxoSmithKline Plc., Teva Pharmaceutical Industries Ltd., Novartis AG, AstraZeneca plc, Boehringer Ingelheim International GmbH, Aptar Pharma (AptarGroup, Inc.), Propeller Health, OPKO Health, Inc., H&T Presspart Manufacturing Ltd., Sensirion AG, and Cohero Health, Inc.
A smart inhaler is mainly a respiratory inhaler that is equipped with a digital sensor. The sensor tracks data such as dosage timing, monitors the use of the inhaler, and schedules the next dosage. Smart Inhalers are able to generate alerts for everyday dosage using smart devices like phones or tablets connected to the sensors via bluetooth. Smart inhalers are designed to treat respiratory disorders such as asthma and COPD.
About the Report
The report on the smart inhalers market offers a comprehensive evaluation of the business opportunities in the smart inhalers market along with insights on the smart inhalers competition blueprint, pricing analysis, epidemiology study, iceberg analysis, list of key distributors, and suppliers in the smart inhalers market for the duration from 2018 to 2026.
The report offers a comprehensive taxonomy of the smart inhalers market on the basis of product type, disease indication, distribution channel, and region. On the basis of product type, the global smart inhalers market has been segmented into DPI-based smart inhalers and MDI-based smart inhalers. On the basis of disease indication, the global smart inhalers market has been segmented into asthma and COPD. On the basis of distribution channel, the global smart inhalers market has been segmented into hospital pharmacies, retail pharmacies, and online pharmacies. From a geographical perspective, the smart inhalers market has been segmented into North America, Latin America, Europe, Asia Pacific (APAC), and Middle East & Africa (MEA).
Request For TOC @ https://www.persistencemarketresearch.com/methodology/26881
The smart inhalers market has been estimated based on a company share analysis approach. A triangulation methodology is adapted to derive the smart inhalers market size, which is primarily based on basis of disease epidemiology, prices of smart inhalers, adoption rate of smart inhalers, and others to obtain market estimations and insights on pharmaceutical and digital companies associated products, technologies, and applications. Furthermore, this information is further validated with primary research (including viewpoints of seasoned analysts, surveys, and interviews) and secondary research (including resourceful databases, authentic trade journals, and verified paid sources). The research study on the smart inhalers market also includes macroeconomic factors and top trends shaping the global smart inhalers market. With this approach, the report on the smart inhalers market projects the industry attractiveness of each major segment in smart inhalers over the forecast period.